₩266,000.00
-4500.00 (-1.66%)
KRW · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where 051910.KS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
62 interventional · 8 observational · 1 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in ChildrenNCT01604395observationalSafety measure : adverse event | — | Recruiting | — | Growth Hormone Deficiency, Turner Syndrome, Chronic Renal Failure, Small for Gestational Age, Idiopathic Short Stature | 6,000 | 2032-12-31 | in 2,324 d | 2021-02-21 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C MutationNCT07752875Phase 1: Number of participants with dose-limiting toxicities (DLTs)Open-label · Treatment | Phase 1/2 | Not yet recruiting | Drug: LG00313112 | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Pancreatic Cancer, Locally Advanced Unresectable or Metastatic Solid Tumor | 250 | 2032-10-31 | in 2,263 d | 2026-08-07 |
| A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious PubertyNCT07710430Peak luteinizing hormone (LH) level following gonadotropin-releasing hormone (GnRH) stimulation is < 4 International Units per Liter (IU/L).Open-label · Treatment | Phase 4 | Recruiting | Drug: Leuprorelin | Central Precocious Puberty | 43 | 2029-08-30 | in 1,105 d | 2026-07-29 |
| Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLCNCT06332755Phase 1a: MTD and/or RP2D of LB-LR1109 as monotherapy in participants with advanced or metastatic solid tumors / Phase 1b: MTD and/or RP2D of LB-LR1109 as combination therapy with atezolizumab in participants with advanced or metastatic NSCLCNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Phase 1a: LB-LR1109, Phase 1b: LB-LR1109 and Atezolizumab | Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC), Urothelial Carcinoma, Malignant Melanoma | 76 | Nov 2027 | ≤ 466 d | 2025-11-24 |
| A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary SeriesNCT06947499Seroprotection/seroconversion rateRandomized · Open-label · Prevention | Phase 2/3 | Recruiting | Biological: LBVD, Pentavalent vaccine and Inactivated Polio vaccine | Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Haemophilus Influenzae Type b | 1,186 | Nov 2026 | ≤ 101 d | 2025-07-03 |
| The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy VolunteersNCT07396844The plasma concentration of Gemigliptin, Dapagliflozin and Metformin.Randomized · Open-label · Treatment | Phase 1 | Not yet recruiting | Drug: Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg | Healthy, Fasting, Fed | 28 | 2026-07-31 | — | 2026-04-13 |
| Phase IV Study to Evaluate the Efficacy and Safety of Fang Le Shu Compared to Guo Na Fen for Controlled Ovarian Stimulation in Infertile Women Undergoing in Vitro Fertilization-embryo Transfer (IVF-ET).NCT06921395Number of oocytes retrievedRandomized · Open-label · Treatment | Phase 4 | Recruiting | Drug: Fang Le Shu (Follitrope), Guo Na Fen (Gonal-F) | Female Infertility | 248 | 2025-09-30 | — | 2025-04-10 |
| Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of AgeNCT06618196Seroprotection/vaccine-response rateRandomized · Triple-masked · Prevention | Phase 2 | Not yet recruiting | Biological: LR20062, DTaP-HepB-IPV-Hib vaccine | Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Haemophilus Influenzae Type B Infection | 336 | 2025-06-30 | — | 2024-10-01 |
| A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metformin is, Compared With Taking Zemiglo and Xigduo XR Together While Fasting.NCT07399470The plasma concentration of Gemigliptin, Dapagliflozin and MetforminRandomized · Open-label · Other | Phase 1 | Completed | Drug: Test drug: Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg, Reference drug: Gemigliptin (Zemiglo) 50mg, Dapagliflozin/metformin (Xigduo XR) 10/1000 mg | Healthy Volunteers, Fasting Conditions | 58 | 2026-02-06actual | — | 2026-07-24 |
| Observational Study of Triple Combination Therapy of Zemidapa Tab. and Metformin in Type 2 Diabetes Mellitus PatientsNCT06495281observationalchange from baseline of HbA1c at 12 weeks | — | Completed | — | Type 2 Diabetes Mellitus | 2,044 | 2025-12-03actual | — | 2026-03-11 |
| A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50/10/1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin/Metformin 10/1000mg in Healthy Adults After a MealNCT07333742The plasma concentration of gemigliptin, dapagliflozin, and metforminRandomized · Open-label · Other | Phase 1 | Completed | Drug: Test drug: Fixed-dose combination (FDC) of gemigliptin/dapagliflozin/metformin 50/10/1000 mg, Reference drug: gemigliptin (Zemiglo) 50mg, Xigduo XR 10/1000 mg | Fed Conditions, Healthy Volunteer | 50 | 2025-11-27actual | — | 2026-01-12 |
| Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary SeriesNCT05457946Seroprotection/seroconservison/ vaccine-response rateRandomized · Open-label · Prevention | Phase 2/3 | Unknown status | Biological: LBVD (Hexavalent vaccine), Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains) | Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Haemophilus Influenzae Type B Infection | 1,438 | 2025-09-30 | — | 2023-03-10 |
| Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout PatientsNCT05586971The proportion of subjects with sUA levels <6.0 mg/dL sustained at months 4, 5, and 6Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Tigulixostat, Allopurinol, Placebo | Gout, Hyperuricemia, Gout Flare, Tophi | 2,202 | 2025-05-06actual | — | 2025-07-22 |
| A Study to Compare Eutropin Formulations in Healthy Volunteers for Bioavailability, Safety, and TolerabilityNCT06743997AUClast of somatropinRandomized · Open-label · Other | Phase 1 | Completed | Drug: Test Drug (Eutropin Catridge, 48IU/Cartridge), Reference Drug (Eutropin, 4 IU/vial) | Healthy Volunteers | 48 | 2025-04-15actual | — | 2025-04-17 |
| A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Genetic ObesityNCT06041841Change of BMIOpen-label · Treatment | Phase 2 | Unknown status | Drug: LB54640 | POMC Deficiency Obesity, PCSK1 Deficiency Obesity, LEPR Deficiency Obesity | 4 | Dec 2024 | — | 2023-11-02 |
| Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in InfantsNCT05431933Immediate reactionRandomized · Open-label · Prevention | Phase 3 | Completed | Biological: Eupolio | Poliomyelitis, Vaccine Reaction | 2,001 | 2024-11-06actual | — | 2025-04-06 |
| Tigulixostat, Phase 3 Study, Placebo Controlled in Gout PatientsNCT05586958The proportion of subjects with sUA levels <6.0 mg/dL sustained at months 4, 5, and 6Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Tigulixostat, Placebo | Gout, Hyperuricemia, Gout Flare, Tophi | 354 | 2024-11-04actual | — | 2025-10-29 |
| A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of LG00034053 in Patients With Knee OANCT05237752Changes in WOMAC (Western Ontario and McMaster Universities Arthritis Index) (11-point NRS) pain score from baseline to time pointRandomized · Quadruple-masked · Treatment | Phase 1/2 | Completed | Drug: LG00034053 | Osteoarthritis, Knee | 74 | 2023-12-19actual | — | 2024-05-03 |
| A Study of LC542019 in Healthy Subjects and Subjects With T2DMNCT06333977Incidence, severity of adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: LC542019, Placebo | Healthy, Diabetes Mellitus, Type 2 | 100 | 2023-12-14actual | — | 2024-03-27 |
| Effect of Tigulixostat on the Pharmacokinetics of TheophyllineNCT06189404AUC0-t of theophylline with and without tigulixostatOpen-label · Basic science | Phase 1 | Completed | Drug: Tigulixostat, Theophylline | Gout, Hyperuricemia | 24 | 2023-11-13actual | — | 2024-01-03 |
| Observational Study Gemigliptin in Patients Aged ≥ 65 Years With Type 2 Diabetes MellitusNCT05281029observationalChange from Baseline of HbA1c at 24 weeks | — | Unknown status | — | Type 2 Diabetes Mellitus | 3,000 | 2023-10-31 | — | 2022-03-16 |
| A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy AdultsNCT05952596Number of subjects with immediate reactionsRandomized · Double-masked · Prevention | Phase 1 | Unknown status | Biological: DTaP-HepB-IPV-Hib vaccine, DTaP-HepB-IPV-Hib vaccine | Diphtheria, Tetanus, Pertussis, Poliomyelitis, Hepatitis B, Haemophilus Influenzae Type b Infection | 42 | 2023-10-31 | — | 2023-07-19 |
| Clinical Investigation of YVOIRE Y-Solution 360 for Lip Augmentation in ChinaNCT05314504Overall LFRS responder rateRandomized · Single-masked · Treatment | Not applicable | Completed | Device: YVOIRE Y-Solution 360 | Lip Augmentation | 174 | 2023-02-23actual | — | 2024-12-19 |
| Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo TransferNCT05130125observationalNumber of Oocytes | — | Completed | Drug: rFSH | Infertility, Female | 1,166 | 2022-12-31actual | — | 2023-08-23 |
| To Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 720 Injected Into the Mid-FaceNCT04437745Asian Faces Mid-Face Volume Deficit Severity Rating Scale (MFVDA-SRS) responder rateRandomized · Single-masked · Treatment | Not applicable | Completed | Device: YVOIRE Y-Solution 720 | Volume Defects in the Mid-face | 238 | 2022-12-13actual | — | 2024-02-09 |
| Effectiveness and Safety of YVOIRE Y-Solution 540NCT04855188WSRS responder rateRandomized · Single-masked · Treatment | Not applicable | Completed | Device: YVOIRE Y-Solution 540, YVOIRE volume plus | Wrinkles in the Nasolabial Folds | 394 | 2022-09-29actual | — | 2024-12-19 |
| A Randomized, Multicenter, Evaluator-Blinded, Active-Controlled, Parallel-Group Investigation to Evaluate the Performance and Safety of YVOIRE® Classic Plus Versus Comparator for Temporary Correction of Nasolabial FoldsNCT05106751Mean change on the Nasolabial Fold Rating Scale (NLFRS) from baseline to Week24.Randomized · Single-masked · Treatment | Phase 4 | Completed | Device: Hyaluronic acid dermal filler | Correction of Nasolabial Folds | 104 | 2022-09-19actual | — | 2023-11-01 |
| A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin AloneNCT04255238Chages from baseline HbA1c at Week24Randomized · Double-masked · Treatment | Phase 3 | Unknown status | Drug: Gemigliptin 50mg, Dapagliflozin 10mg | Diabetes Mellitus, Type 2 | 468 | 2022-05-30 | — | 2020-02-19 |
| Clinical Study to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 720 Injected for Jawline ContouringNCT04886544The primary effectiveness endpoint is the Jawline Contour Rating Scale (JCRS) responder rate at 26 weeks after the last injectionRandomized · Single-masked · Treatment | Not applicable | Completed | Device: YVOIRE Y-Solution 720 | Jaw Volume Deficit | 72 | 2022-05-11actual | — | 2023-05-12 |
| To Evaluate the Performance and Safety of YVOIRE Volume Plus for Improvement of Mid-face VolumeNCT04784299Non-inferiority of YVOIRE volume plus versus Restylane Lyft with LidocaineRandomized · Single-masked · Treatment | Not applicable | Completed | Device: YVOIRE volume plus, Restylane Lyft with Lidocaine | Midface Volume Deficit | 105 | 2022-04-11actual | — | 2024-12-19 |
| A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese SubjectsNCT06040372Incidence and severity of adverse events (AEs)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: LB64640, Placebo | Obese, Overweight, Healthy | 112 | 2022-03-30actual | — | 2023-09-15 |
| A Multicenter, Prospective Observational Study to Evaluate the Incidence of Delayed-onset Nodules of YVOIRE Y-Solution 360, YVOIRE Y-Solution 540 or YVOIRE Y-Solution 720 Injected Into the Facial Skin Layer.NCT04738019observationalDelayed-onset nodule. | — | Completed | Diagnostic test: Medical examination or treatment. | Healthy Condition | 1,022 | 2022-02-28actual | — | 2023-01-12 |
| Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mgNCT05105698Peak Plasma Concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Unknown status | Drug: gemigliptin and dapagliflozin 50/10 mg film-coated tablet (Fasting), gemigliptin and dapagliflozin 50/10 mg film-coated tablet (fed) | Healthy Volunteers | 28 | 2022-02-28 | — | 2021-11-03 |
| To Evaluate Safety and Effectiveness of RovatitanTab.NCT04398771observationalThe ratio of patients who reach the target BP | — | Unknown status | Drug: Rosuvastatin/Valsartan | Hypertension, Hyperlipidemias | 1,000 | 2022-01-31 | — | 2020-05-21 |
| A Phase I Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of TT-01025-CL in Healthy SubjectsNCT04730050Adverse EventsRandomized · Double-masked · Treatment | Phase 1 | Unknown status | Drug: TT-01025-CL | Healthy | 64 | Dec 2021 | — | 2021-11-24 |
| Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female SubjectsNCT04966325The placebo-corrected change from baseline in QTcFRandomized · Double-masked · Treatment | Early Phase 1 | Completed | Drug: LC350189 200mg, Placebo, Moxifloxacin 400mg, LC350189 600mg | Hyperuricemia, Gout, Qt Interval, Variation in | 37 | 2021-12-07actual | — | 2022-01-06 |
| Efficacy and Safety of LC51-0255 in Subjects With Ulcerative ColitisNCT04096573Clinical remissionRandomized · Double-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: company decision | Drug: LC51-0255, Placebo | Ulcerative Colitis | 0 | Nov 2021 | — | 2021-11-15 |
| Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy AdultsNCT04886050The relative bioavailability of LC350189 after administration via tablet formulation compared with capsule formulation by assessment of the area under the plasma concentration-time curve from zero to infinity for the tablet formulation capsule formationRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: LC350189 Tablet, LC350189 Capsule | Gout, Hyperuricemia | 23 | 2021-09-16actual | — | 2022-01-06 |
| To Assess the Safety and Effectiveness of Hyruan ONE Versus a Comparator for the Treatment of Knee Osteoarthritis in EuropeNCT04732793The change in the WOMAC(Western Ontario and McMaster Universities Osteoarthritis Index) Likert pain subscoreRandomized · Double-masked · Treatment | Not applicable | Completed | Device: Hyruan ONE®, Durolane® | Osteoarthritis (OA) of the Knee | 284 | 2021-06-11actual | — | 2022-03-16 |
| A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)NCT03842267Changes from baseline HbA1c at week 24Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Gemigliptin 50mg, Gemigliptin Placebo | Diabetes Mellitus, Type 2 | 315 | 2021-05-20actual | — | 2023-03-10 |
| A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With HyperuricemiaNCT03934099results2025-12-03Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: LC350189 formulated capsule, Placebo | Gout, Hyperuricemia | 156 | 2021-05-03actual | — | 2025-12-03 |
| Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin/Dapagliflozin 50/10 mgNCT04544319Gemigliptin and dapagliflozin AUClast and CmaxRandomized · Open-label · Other | Phase 1 | Unknown status | Drug: Zemiglo 50mg and Forxiga 10mg, Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg | T2DM | 44 | Mar 2021 | — | 2020-09-11 |
| To Evaluate the Performance and Safety of YVOIRE Y Solution 360 Versus Comparator for Lips and Perioral Area.NCT04299295Mean change on the overall Lip Fullness Rating Scale (LFRS) from baseline to Week12.Randomized · Single-masked · Treatment | Not applicable | Terminatedsponsor's stated reason: Due to company's internal decision. | Device: YVOIRE Y-Solution 360, Juvéderm VOLBELLA | Lip Augmentation | 118 | 2020-12-07actual | — | 2021-10-14 |
| A Study of YVOIRE Y-Solution 360 for Hand Augmentation to Correct Volume LossNCT04112017≥ 1 grade improvement on Hand Volume Rating Scale (HVRS) as assessed by the evaluator-blindedRandomized · Single-masked · Treatment | Not applicable | Terminatedsponsor's stated reason: Sponsor's decision | Device: YVOIRE Y-Solution 360 | Dorsal Hand Volume Loss | 116 | 2020-10-14actual | — | 2021-01-22 |
| A Phase IV Study to Assess the Safety of EupentaTM InjNCT04056728Incidence of any immediate reactions reported from the study after EupentaTM Inj. VaccinationOpen-label · Prevention | Phase 4 | Unknown status | Biological: Eupenta Inj. | Hepatitis B, Diphtheria, Haemophilus Influenzae Type B Infection, Tetanus, Pertussis | 3,000 | 2020-10-12 | — | 2019-08-14 |
| Compare the Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of LC51-0255 Film-coated Tablet (SG85) With LC51-0255 Uncoated Tablet (SG82) in Healthy SubjectsNCT04360343Pharmacokinetic Outcome MeasuresRandomized · Open-label · Other | Phase 1 | Completed | Drug: Film-coated tablet | Ulcerative Colitis | 18 | 2020-10-01actual | — | 2021-01-22 |
| Renal PK Study of LC350189NCT04066712AUC from time 0 to the last quantifiable concentrationNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: LC350189 200 mg | Gout, Hyperuricemia | 37 | 2020-09-12actual | — | 2020-09-21 |
| Bioequivalence Study for Fixed Dose Combination Zemimet® SR Tab. 50/1000 and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.NCT04317703bioequivalence studyRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Gemigliptin tartrate sesquihydrate and metformin, gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release | Type 2 Diabetes | 40 | 2020-09-05actual | — | 2021-02-09 |
| Observational Study to Develop Dosing ChartNCT04227171observationalNo. of oocytes retrieved No. of oocytes retrieved Number of oocyte retrieved | — | Completed | — | Infertile Women Undergoing IVF or ICSI | 534 | 2020-07-31actual | — | 2020-08-07 |
| Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy InfantsNCT04073459seroprotection/seroconversion/vaccine-response rateRandomized · Open-label · Prevention | Phase 2 | Unknown status | Biological: DTwP-HepB-Sabin IPV-Hib, Pentavalent vaccine and Salk IPV | Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Haemophilus Influenzae Type b Infection | 336 | Apr 2020 | — | 2019-09-06 |
| Mass Balance Study of [14C]LC350189 in Healthy VolunteersNCT04070846Mass balance recovery of total radioactivity in whole blood and plasma.Open-label · Treatment | Phase 1 | Completed | Drug: [14C] LC350189 | Gout, Hyperuricemia | 6 | 2020-03-07actual | — | 2020-06-26 |
| The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy AdultsNCT04139824Maximun observed concentration (Cmax) of LC350189 and Naproxen from plasmaOpen-label · Treatment | Phase 1 | Completed | Drug: Xanthine Oxidase Inhibitor, nonsteroidal anti-inflammatory drug | Gout, Hyperuricemia | 24 | 2020-02-25actual | — | 2020-06-26 |
| 6x3 Crossover, Bioavailability, Safety and Tolerability Among Different Eutropin Formulations in Healthy VolunteersNCT04085224BioavailabilityRandomized · Single-masked · Other | Phase 1 | Completed | Drug: Somatropin | Bioavailability, Safety and Tolerability Among Different Eutropin Formulations in Healthy Volunteers | 24 | 2020-01-02actual | — | 2020-03-24 |
| Bioequivalence Study for Gemigliptin/Metformin 50/1000 mg and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.NCT04050098bioequivalence studyRandomized · Open-label · Treatment | Phase 1 | Unknown status | Drug: gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release, Gemigliptin tartrate sesquihydrate and metformin | Type2 Diabetes | 24 | 2019-11-30 | — | 2019-08-08 |
| Food-effect Bioavailability of Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg Under Fed and Fasting ConditionsNCT04070794Peak Plasma Concentration (Cmax) of gemigliptin, LC 15-0636 and metforminRandomized · Open-label · Treatment | Phase 1 | Unknown status | Drug: Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fasting), Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fed) | Type2 Diabetes | 24 | 2019-11-30 | — | 2019-08-28 |
| The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.NCT03927677Maximun observed concentration (Cmax) of LC350189 and Colchicine from plasmaOpen-label · Treatment | Phase 1 | Completed | Drug: Xanthine Oxidase Inhibitor | Gout, Hyperuricemia | 24 | 2019-11-26actual | — | 2020-06-26 |
| An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I)NCT03864432AUClast of GemigliptinNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Gemigliptin 25mg, Gemigliptin 50mg, Gemigliptin 100mg, Gemiglptin 50mg multiple dose | Type 2 Diabetes Mellitus | 48 | 2019-10-03actual | — | 2020-03-03 |
| Observational Study of Synovian® Inj. in Patients With Osteoarthritis in the KneeNCT04369261observationalsafety endpoints | — | Completed | Drug: Synovian® | Osteoarthritis in the Knee | 1,949 | 2019-08-08actual | — | 2020-04-30 |
| A Study To Evaluate The Safety, Pharmacokinetics/Pharmacodynamics (PK/PD) and Food Effect Of LC51-0255NCT03174613MTD determinationRandomized · Double-masked · Basic science | Phase 1 | Completed | Drug: LC51-0255, Placebo | Healthy | 100 | 2019-06-12actual | — | 2020-09-18 |
| BE Study of Bilayer Combination of Gemigliptin/Rosuvastatin 50/20mg in Comparison to Monolayer Combination.NCT03867942Gemigliptin AUCRandomized · Open-label · Treatment | Phase 1 | Unknown status | Drug: Monolayer group, Bilayer group | Diabetes Mellitus, Type 2, Dyslipidemias | 48 | 2019-05-24 | — | 2019-03-08 |
| A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy AdultsNCT03549208Solicited adverse eventsRandomized · Single-masked · Prevention | Phase 1 | Unknown status | Biological: LBVE01, LBVE02, Prevnar13 | Pneumococcal Infection | 60 | 2019-04-01 | — | 2018-06-13 |
| A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy InfantsNCT03169725Stage1: Seroconversion rate(%)Randomized · Triple-masked · Prevention | Phase 2/3 | Completed | Biological: Inactivated Poliomyelitis Vaccine (Sabin strain), Inactivated Poliomyelitis Vaccine (Salk strain) | Poliomyelitis | 1,417 | 2019-01-18actual | — | 2019-08-29 |
| A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy InfantsNCT03467984Proportion of subjects achieving pneumococcal serotype-specific IgG >= 0.35 ug/mlRandomized · Single-masked · Prevention | Phase 2 | Completed | Biological: LBVE, Prevnar13 | Pneumococcal Infection | 230 | 2018-10-05actual | — | 2019-08-22 |
| Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802NCT03532854AUCT,ssRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Valsartan, Ezetimibe/Rosuvastatin | Healthy Male Volunteers | 42 | 2018-08-25actual | — | 2019-02-15 |
| Gemigliptin, Dapagliflozin, Empagliflozin DDI StudyNCT03565458Area under the plasma concentration versus time curve (AUC) of gemigliptin, dapagliflozin, empagliflozinRandomized · Open-label · Treatment | Phase 1 | Unknown status | Drug: Gemigliptin, Dapagliflozin, Empagliflozin | Type 2 Diabetes Mellitus | 48 | 2018-08-20 | — | 2018-06-21 |
| Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)NCT03202563Changes from baseline MAGE(Mean amplitude of glycemic excursion) at week 12Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Gemigliptin 50mg, Dapagliflozin 10mg, Metformin · Procedure: Diet/exercise questionnaire · Device: Continuous Glucose Monitoring System(CGMS) | Type 2 Diabetes Mellitus | 71 | 2018-07-13actual | — | 2019-02-15 |
| BE Study of the Combinations of Gemigliptin/Metformin HCl Extended Release 50/1000mg(25/500mg x 2 Tablets) in Comparison to Each Component Administered AloneNCT03355014AUClastRandomized · Open-label · Other | Phase 1 | Completed | Drug: Combination of gemigliptin/metformin HCl sustained release 50/1000mg, Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg | Healthy Male Volunteers | 70 | 2018-01-12actual | — | 2018-02-22 |
| A Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126.NCT03196804Adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: LC28-0126, Placebo | Healthy | 32 | 2017-11-15actual | — | 2018-04-11 |
| A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy AdultsNCT03208101Number of subjects with immediate reactionsRandomized · Open-label · Prevention | Phase 1 | Completed | Biological: DTP-HepB-IPV-Hib vaccine, DTP-HepB-Hib vaccine & IPV | Diphtheria, Tetanus, Pertussis, Poliomyelitis, Hepatitis B, Haemophilus Influenzae Type b Infection | 42 | 2017-09-06actual | — | 2019-08-29 |
| Relative Bioavailability Among Different Eutropin FormulationsNCT03154840AUClast of somatropinRandomized · Open-label · Health services research | Phase 1 | Unknown status | Drug: Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU | Relative Bioavailability | 24 | 2017-07-10actual | — | 2017-07-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19